anti-inflammatory therapies for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. adjuvant therapies
vs. paracetamol
vs. antiviral and associated therapy
vs. hydroxychloroquine plus macrolides
vs. azithromycin plus hydroxychloroquine
vs. control
vs. placebo
vs. standard of care

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 0

table network network 2

display ongoing demontrated benefit only

popup

COLCHIVID, 2021 NCT04367168

colchicine vs. placebo

COVID-19 severe or critically

Brunetti, 2020

colchicine vs. standard of care

COVID-19 severe or critically

NCT04447469, 0 NCT04447469

mavrilimumab vs. placebo

COVID-19 severe or critically

LIBA, 0 NCT04334629

naproxen, ibuprofen vs. standard of care

COVID-19 severe or critically

ENACOVID, 0 NCT04325633

naproxen, ibuprofen vs. standard of care

COVID-19 severe or critically

STROMA-CoV2, 0 NCT04333368

stem cells vs. placebo

COVID-19 severe or critically

Shi, 2020 NCT04288102

stem cells vs. placebo

COVID-19 severe or critically

NCT04336254, 2020 NCT04336254

stem cells vs. standard of care

COVID-19 severe or critically

Shu, 2020 ChiCTR2000031494

stem cells vs. standard of care

COVID-19 severe or critically

PANAMO, 0 NCT04333420

vilobelimab (IFX-1) vs. standard of care

COVID-19 severe or critically

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open